Novo Nordisk A/S $NVO Position Reduced by Boston Family Office LLC

Boston Family Office LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 5.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,673 shares of the company’s stock after selling 2,175 shares during the quarter. Boston Family Office LLC’s holdings in Novo Nordisk A/S were worth $2,462,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Revolve Wealth Partners LLC grew its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Novo Nordisk A/S in the first quarter worth $41,000. XTX Topco Ltd purchased a new position in shares of Novo Nordisk A/S during the first quarter valued at $706,000. US Bancorp DE grew its holdings in shares of Novo Nordisk A/S by 1.0% during the first quarter. US Bancorp DE now owns 338,470 shares of the company’s stock valued at $23,504,000 after buying an additional 3,493 shares in the last quarter. Finally, Moors & Cabot Inc. raised its position in Novo Nordisk A/S by 10.7% during the first quarter. Moors & Cabot Inc. now owns 6,875 shares of the company’s stock valued at $477,000 after buying an additional 663 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.3%

Shares of NYSE NVO opened at $49.35 on Monday. The stock has a market cap of $220.33 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 2.33 and a beta of 0.65. The business has a 50 day simple moving average of $52.81 and a 200 day simple moving average of $59.66. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $112.52. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of research reports. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating for the company. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Finally, Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $56.83.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.